妊娠期母体全身性糖皮质激素暴露与儿童慢性肾脏病风险
本研究基于台湾2004至2018年最大医疗体系的新生儿回顾性队列,纳入23,363名单胎出生儿童,评估妊娠期母体全身性糖皮质激素暴露与儿童期慢性肾脏病(CKD)的关联。结果显示暴露与儿童期CKD风险显著升高相关(AHR 1.69,95%CI 1.01-2.84),且在早产、男性、孕中期暴露及氢化可的松等效剂量>24mg亚组中关联更强。
要点
- 妊娠期全身性糖皮质激素暴露与儿童期CKD风险升高相关(AHR 1.69)。
- 孕中期暴露、剂量>24mg氢化可的松等效及早产儿中关联更强。
- 需确认后可为孕期处方全身性糖皮质激素提供参考。
核心结论
- 妊娠期全身性糖皮质激素暴露与儿童期肾脏疾病发生相关。
研究设计与样本
- 回顾性队列研究,纳入台湾2004至2018年最大医疗体系23,363名单胎出生儿童。
主要发现
- gestational systemic glucocorticoid exposure was significantly associated with a higher risk of childhood CKD (AHR, 1.69 [95% CI, 1.01-2.84]).
- Birth<37 weeks' gestational age stratum: AHR 2.38 (95% CI, 1.19-4.78).
- Male sex stratum: AHR 1.89 (95% CI, 1.00-3.55).
- Second trimester exposure stratum: AHR 6.70 (95% CI, 2.17-20.64).
- Total dose >24mg hydrocortisone equivalent stratum: AHR 1.91 (95% CI, 1.05-3.47).
临床怎么用
- 若 findings 被确认,可 inform clinicians considering prescribing systemic glucocorticoids during pregnancy.
局限性
- 研究限于台湾医疗体系且儿童CKD事件随访至10岁。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The potential effects of antenatal glucocorticoid exposure on the health of children are unclear. We examined the association of gestational exposure to maternal systemic glucocorticoids and the risk of developing chronic kidney disease (CKD) in childhood. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Newborns cared for at the largest health care delivery system in Taiwan between 2004 and 2018. EXPOSURE: Maternal prescriptions for systemic glucocorticoids between the last menstrual period and birth as a proxy for gestational exposure. OUTCOME: Incidence of childhood CKD, including congenital anomalies of the kidney and urinary tract (CAKUT) and other kidney diseases (non-CAKUT), over 10 years. ANALYTICAL APPROACH: Cox proportional hazards models with stabilized inverse probability of treatment weighting and robust sandwich estimator were used to estimate the average association between systemic glucocorticoids and incident CKD after adjustment for offspring characteristics (adjusted HR: AHR). RESULTS: Among 23,363 singleton-born children, gestational systemic glucocorticoid exposure was significantly associated with a higher risk of childhood CKD (AHR, 1.69 [95% CI, 1.01-2.84]). Stratified analyses showed stronger associations between systemic glucocorticoids and childhood CKD within the strata of birth<37 weeks' gestational age (AHR, 2.38 [95% CI, 1.19-4.78]), male sex (AHR, 1.89 [95% CI, 1.00-3.55]), gestational exposure in the second trimester (AHR, 6.70 [95% CI, 2.17-20.64]), and total dose of>24mg hydrocortisone equivalent (AHR, 1.91 [95% CI, 1.05-3.47]). LIMITATIONS: Study was limited to the Taiwan health care delivery system and childhood CKD events through the age of 10 years. CONCLUSIONS: The findings of this study suggest that gestational exposure to systemic glucocorticoids is associated with the occurrence of kidney disease in childhood. If these findings are confirmed, they may inform clinicians who are considering prescribing systemic glucocorticoids during pregnancy. PLAIN-LANGUAGE SUMMARY: In a singleton-born cohort of neonates, maternal exposure to antenatal systemic glucocorticoids was significantly associated with a 1.7-fold increased risk of the children developing chronic kidney disease over the first 10 years of life. Children of mothers who received>24mg of hydrocortisone equivalent, systemic glucocorticoid treatment in second trimester of gestation, and children born at<37 weeks of gestational age had a higher risk of childhood kidney disease after gestational systemic glucocorticoid exposure. If these findings are confirmed, they may inform clinicians who are considering prescribing systemic glucocorticoids during pregnancy.
引用
- Tain YL, Li LC, Kuo HC, et al. Gestational Exposure to Maternal Systemic Glucocorticoids and Childhood Risk of CKD. Am J Kidney Dis. 2024. PMID: 38479460. doi:10.1053/j.ajkd.2024.01.523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。